CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
PD-1/PD-L1 inhibitor therapy: transitioning from a second-line to a first-line therapy for non-small cell lung cancer
Jong-Mu Sun
Precis Future Med. 2017;1(1):3-9.   Published online March 31, 2017

Excel Download

PD-1/PD-L1 inhibitor therapy: transitioning from a second-line to a first-line therapy for non-small cell lung cancer
Precision and Future Medicine. 2017;1(1):3-9   Crossref logo
Link1 Link2 Link3

Personalized PD-1/PD-L1 inhibitor therapy for advanced non small cell lung cancer beyond first line; a meta-analysis of potential predictive factors
Annals of Oncology. 2016;27:vi373   Crossref logo
Link1 Link2 Link3

Network Meta-Analysis of First-Line Immune Checkpoint Inhibitor Therapy in Advanced Non-Squamous Non-Small Cell Lung Cancer Patients with PD-L1 Expression ≥50%
. 2023;   Crossref logo
Link1 Link2

Network meta-analysis of first-line immune checkpoint inhibitor therapy in advanced non-squamous non-small cell lung cancer patients with PD-L1 expression ≥ 50%
BMC Cancer. 2023;23(1):   Crossref logo
Link1 Link2 Link3

Clinical Outcomes for PD-1 Inhibitor Plus Chemotherapy as Second-Line or Later Therapy Compared to PD-1/PD-L1 Inhibitor Alone in Advanced Non-small-cell Lung Cancer
Frontiers in Oncology. 2020;10:   Crossref logo

406P Anti-PD-1 versus anti-PD-L1 inhibitors in first-line therapy non-small-cell lung cancer: A systematic review and meta-analysis
Annals of Oncology. 2020;31:S1401   Crossref logo
Link1 Link2

First-line pembrolizumab in PD-L1 positive non-small-cell lung cancer: A cost-effectiveness analysis from the UK health care perspective
Lung Cancer. 2018;123:166-171   Crossref logo
Link1 Link2

First-line PD-1/PD-L1 inhibitor plus chemotherapy vs chemotherapy alone for negative or < 1% PD-L1-expressing metastatic non-small-cell lung cancers
Journal of Cancer Research and Clinical Oncology. 2019;146(2):441-448   Crossref logo
Link1 Link2 Link3

Use of PD-L1 Biomarker in Second Line Therapy for Non-Small Cell Lung Cancer: Budget Impact Analysis from a Private Payer Perspective In Brazil
Value in Health. 2018;21:S23   Crossref logo
Link1 Link2

1119P Real-world efficacy and safety of anlotinib in combination with PD-1/PD-L1 inhibitors as first-line or second-line treatment in advanced non-small cell lung cancer
Annals of Oncology. 2022;33:S1063   Crossref logo
Link1 Link2